Division of Radiation Effects, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea.
Radiat Oncol. 2012 Mar 27;7:47. doi: 10.1186/1748-717X-7-47.
Previously, we found that β-galactoside α2,6-sialyltransferase (ST6Gal I), an enzyme that adds sialic acids to N-linked oligosaccharides of glycoproteins and is frequently overexpressed in cancer cells, is up-regulated by ionizing radiation (IR) and cleaved to a form possessing catalytic activity comparable to that of the Golgi-localized enzyme. Moreover, this soluble form is secreted into the culture media. Induction of ST6Gal I significantly increased the migration of colon cancer cells via sialylation of integrin β1. Here, we further investigated the mechanisms underlying ST6Gal I cleavage, solubilization and release from cells, and addressed its functions, focusing primarily on cancer cell migration.
We performed immunoblotting and lectin affinity assay to analyze the expression of ST6 Gal I and level of sialylated integrin β1. After ionizing radiation, migration of cells was measured by in vitro migration assay. α2, 6 sialylation level of cell surface was analyzed by flow cytometry. Cell culture media were concentrated and then analyzed for soluble ST6Gal I levels using an α2, 6 sialyltransferase sandwich ELISA.
We found that ST6Gal I was cleaved by BACE1 (β-site amyloid precursor protein-cleaving enzyme), which was specifically overexpressed in response to IR. The soluble form of ST6Gal I, which also has sialyltransferase enzymatic activity, was cleaved from the Golgi membrane and then released into the culture media. Both non-cleaved and cleaved forms of ST6Gal I significantly increased colon cancer cell migration in a sialylation-dependent manner. The pro-migratory effect of the non-cleaved form of ST6Gal I was dependent on integrin β1 sialylation, whereas that of the cleaved form of ST6Gal I was not, suggesting that other intracellular sialylated molecules apart from cell surface molecules such as integrin β1 might be involved in mediating the pro-migratory effects of the soluble form of ST6Gal I. Moreover, production of soluble form ST6Gal I by BACE 1 inhibited integrin β1 sialylation and migration by Golgi-anchored form of ST6Gal I.
Our results suggest that soluble ST6Gal I, possibly in cooperation with the Golgi-bound form, may participate in cancer progression and metastasis prior to being secreted from cancer cells.
此前,我们发现β-半乳糖苷α2,6-唾液酸转移酶(ST6Gal I),一种能在糖蛋白的 N 连接寡糖上添加唾液酸的酶,在癌细胞中常过度表达,可被电离辐射(IR)上调,并被切割成一种具有与高尔基定位酶相当的催化活性的形式。此外,这种可溶性形式被分泌到培养基中。ST6Gal I 的诱导显著增加了整合素β1的唾液酸化,从而增加了结肠癌细胞的迁移。在这里,我们进一步研究了 ST6Gal I 裂解、溶解和从细胞中释放的机制,并主要集中研究其功能,重点是研究癌症细胞的迁移。
我们进行了免疫印迹和凝集素亲和测定,以分析 ST6Gal I 的表达和整合素β1的唾液酸化水平。在电离辐射后,通过体外迁移测定来测量细胞的迁移。通过流式细胞术分析细胞表面的α2,6 唾液酸化水平。浓缩细胞培养物培养基,然后使用α2,6 唾液酸转移酶夹心 ELISA 分析可溶性 ST6Gal I 水平。
我们发现 ST6Gal I 可被 BACE1(β-位淀粉样前体蛋白切割酶)切割,BACE1 特异性地在受到 IR 时过度表达。具有唾液酸转移酶酶活性的 ST6Gal I 的可溶性形式从高尔基体膜上裂解下来,然后释放到培养基中。非裂解形式和裂解形式的 ST6Gal I 均以唾液酸化依赖的方式显著增加结肠癌细胞的迁移。非裂解形式的 ST6Gal I 的促迁移作用依赖于整合素β1的唾液酸化,而裂解形式的 ST6Gal I 的促迁移作用则不依赖,这表明除了整合素β1等细胞表面分子之外,其他细胞内的唾液酸化分子可能参与介导可溶性 ST6Gal I 的促迁移作用。此外,BACE1 产生的可溶性 ST6Gal I 抑制了高尔基锚定形式的 ST6Gal I 对整合素β1的唾液酸化和迁移。
我们的结果表明,可溶性 ST6Gal I 可能与高尔基结合形式一起,在从癌细胞中分泌之前,可能参与癌症的进展和转移。